Global Seroprevalence and Sociodemographic Characteristics of Borrelia Burgdorferi Sensu Lato in Human Populations: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Yan Dong ◽  
Peng Yue ◽  
Guozhong Zhou ◽  
Wenjing Cao ◽  
Xin Xu ◽  
...  
2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Rosemond Qian-Xiu Tan ◽  
Wai Tak Victor Li ◽  
Wing-Zi Shum ◽  
Sheung Chit Chu ◽  
Hang-Long Li ◽  
...  

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients. Methods This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases China National Knowledge Infrastructure (CNKI), VIP and WANFANG, will be searched using keywords including ‘COVID-19’, ‘coronavirus disease’, ‘2019-nCoV’, ‘SARS-CoV-2’, ‘novel coronavirus’, ‘anosmia’, ‘hyposmia’, ‘loss of smell’, and ‘olfactory dysfunction’. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3. Discussion This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate broad clinical data for robust statistical analyses and representation. The outcome of the systematic review and meta-analysis will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect. Systematic review registration PROSPERO registration number: CRD42020196202.


2021 ◽  
Author(s):  
Rosemond Qian-Xiu Tan ◽  
Wai Tak Victor Li ◽  
Wing-Zi Shum ◽  
Sheung Chit Chu ◽  
Hang-Long Li ◽  
...  

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients. Methods This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases: China National Knowledge Infrastructure (CNKI), VIP and WANFANG will be searched using keywords including “COVID-19”, “coronavirus disease”, “2019-nCoV”, “SARS-CoV-2”, “novel coronavirus”, “anosmia”, “hyposmia”, “loss of smell”, and “olfactory dysfunction”. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3. Discussion This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate broad clinical data for robust statistical analyses and representation. The outcome of the systematic review and meta-analysis will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.Systematic Review registration: PROSPERO registration number: CRD42020196202


2018 ◽  
Vol 24 (3) ◽  
pp. 252-264 ◽  
Author(s):  
Ahmed U. Mishuk ◽  
Jingjing Qian ◽  
Jennifer N. Howard ◽  
Ilene Harris ◽  
Gavriella Frank ◽  
...  

2021 ◽  
Author(s):  
Rosemond Qian-Xiu Tan ◽  
Wai Tak Victor Li ◽  
Wing-Zi Shum ◽  
Sheung Chit Chu ◽  
Hang-Long Li ◽  
...  

Abstract BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients. MethodsThis research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases: China National Knowledge Infrastructure (CNKI), VIP and WANFANG will be searched using keywords including “COVID-19”, “coronavirus disease”, “2019-nCoV”, “SARS-CoV-2”, “novel coronavirus”, “anosmia”, “hyposmia”, “loss of smell”, and “olfactory dysfunction”. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3. DiscussionThis systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate comprehensive clinical data for robust statistical analyses and representation. The outcome of this study will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.Systematic Review registration: PROSPERO registration number: CRD42020196202


2021 ◽  
Vol 12 ◽  
Author(s):  
Claire Rennie ◽  
Ritin Fernandez ◽  
Sheila Donnelly ◽  
Kristine CY McGrath

BackgroundThere are a growing number of publications that report an absence of inflammatory based disease among populations that are endemic to parasitic worms (helminths) demonstrating the ability of these parasites to potentially regulate human immune responses. The aim of this systematic review and meta-analysis was to determine the impact of helminth infection on metabolic outcomes in human populations.MethodsUsing PRISMA guidelines, six databases were searched for studies published up to August 2020. Random effects meta-analysis was performed to estimate pooled proportions with 95% confidence intervals using the Review Manager Software version 5.4.1.ResultsFourteen studies were included in the review. Fasting blood glucose was significantly lower in persons with infection (MD -0.22, 95% CI -0.40- -0.04, P=0.02), HbA1c levels were lower, although not significantly, and prevalence of the metabolic syndrome (P=0.001) and type 2 diabetes was lower (OR 1.03, 95% CI 0.34-3.09, P<0.0001). Infection was negatively associated with type 2 diabetes when comparing person with diabetes to the group without diabetes (OR 0.44, 95% CI 0.29-0.67, P=0.0001).ConclusionsWhile infection with helminths was generally associated with improved metabolic function, there were notable differences in efficacy between parasite species. Based on the data assessed, live infection with S. mansoni resulted in the most significant positive changes to metabolic outcomes.Systematic Review RegistrationWebsite: PROSPERO Identified: CRD42021227619.


2020 ◽  
Author(s):  
Rosemond Qian-Xiu Tan ◽  
Wai Tak Victor Li ◽  
Wing-Zi Shum ◽  
Sheung Chit Chu ◽  
Hang-Long Li ◽  
...  

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients. Methods This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases: China National Knowledge Infrastructure (CNKI), VIP and WANFANG will be searched using keywords including “COVID-19”, “coronavirus disease”, “2019-nCoV”, “SARS-CoV-2”, “novel coronavirus”, “anosmia”, “hyposmia”, “loss of smell”, and “olfactory dysfunction”. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3. Discussion This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate comprehensive clinical data for robust statistical analyses and representation. The outcome of this study will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.Systematic Review registration: PROSPERO registration number: CRD42020196202


2020 ◽  
Author(s):  
Rosemond Qian-Xiu Tan ◽  
Wai Tak Victor Li ◽  
Wing-Zi Shum ◽  
Sheung Chit Chu ◽  
Hang-Long Li ◽  
...  

Abstract BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which COVID-19-related olfactory dysfunction (OD) has been recognised as an important and common symptom of COVID-19 infection. The aim of this study is to conduct a systematic review and meta-analysis of peer-reviewed articles, which described clinical data of smell disturbances and OD in COVID-19 patients.MethodsThis research protocol has been prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). Accordingly, PubMed (MEDLINE) articles published from 1st January 2020 to 10th June 2020 will be searched using the following keywords: COVID-19, SARS-CoV-2, 2019-nCoV, or novel coronavirus. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to the pre-specified inclusion and exclusion criteria. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3.DiscussionThis systematic review and meta-analysis will exclusively evaluate OD as a symptom of COVID-19 infection. We aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD. A comprehensive search strategy and screening process will be used to ensure that all relevant clinical data are included for statistical analysis and representation. The outcome of this study will improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and serves to identify knowledge gaps in its disease process, which will guide future research regarding this specific neurosensory impairment.Systematic Review registration: PROSPERO registration number: CRD42020196202


Sign in / Sign up

Export Citation Format

Share Document